Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Payables (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Payables for 10 consecutive years, with $4.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 282.11% to $4.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.1 million, a 282.11% increase, with the full-year FY2024 number at $911000.0, down 23.45% from a year prior.
  • Payables was $4.1 million for Q3 2025 at Rein Therapeutics, down from $6.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $6.0 million in Q2 2025 to a low of $136000.0 in Q2 2023.
  • A 5-year average of $1.5 million and a median of $1.0 million in 2021 define the central range for Payables.
  • Peak YoY movement for Payables: crashed 92.19% in 2023, then soared 670.84% in 2025.
  • Rein Therapeutics' Payables stood at $1.2 million in 2021, then skyrocketed by 42.15% to $1.7 million in 2022, then plummeted by 30.81% to $1.2 million in 2023, then dropped by 23.45% to $911000.0 in 2024, then soared by 352.58% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Payables are $4.1 million (Q3 2025), $6.0 million (Q2 2025), and $1.1 million (Q1 2025).